This article is more than 5 years old. Information may no longer be current.
Top stories in hematology and oncology: new tumor screening method, lower breast cancer recurrence factors
Among the top stories in hematology and oncology is that upfront tumor screening for Lynch syndrome may be more beneficial than the current approach among patients with colorectal cancer. Combination therapy with BRAF and MEK inhibitors should be the preferred treatment option for patients with low-burden metastatic melanoma. Other stories include five deaths have occurred among patients being treated for hemophilia with emicizumab-kxwh, factors associated with lower breast cancer recurrence have been identified, and the FDA confirmed breast-implant associated lymphoma is more common than originally predicted. – by Jake Scott
Tumor sequencing superior to other methods of detecting Lynch syndrome in colorectal cancer
Upfront tumor screening for Lynch syndrome appeared simpler and demonstrated superior sensitivity than the current multiple sequential test approach among patients with colorectal cancer, study data showed. Read More.
BRAF/MEK inhibitor therapy a preferred option for metastatic melanoma
Combination therapy with BRAF and MEK inhibitors can confer long-term survival for patients with low-burden metastatic melanoma and should be a preferred treatment option, according to a presenter at HemOnc Today New York. Read More.
Five patient deaths occurred while using Hemlibra
Five patients have died since 2016 while being treated with emicizumab-kxwh for hemophilia A, according to the manufacturer. Read More.
Researchers identify factors associated with lower breast cancer recurrence risk
Postmenopausal women and those with ER-positive tumors appeared less likely to experience ductal carcinoma in situ recurrence, according to results of a retrospective analysis presented at the European Breast Cancer Conference. Read More.
Breast implant-associated lymphoma more common than originally predicted
The FDA provided updated information regarding risk for breast-implant associated anaplastic large cell lymphoma. Read More.